Diabetes Franchise May Help Merck Offset Loss Of Singulair
This article was originally published in The Pink Sheet Daily
Executive Summary
The Januvia/Janumet franchise posted sales growth of 40% both in the fourth quarter and over the full year for Merck, while Isentress and Gardasil also posted strong growth rates.
You may also be interested in...
High-Premium Buyouts Continue In Hepatitis C Space; Are Idenix And Achillion Next?
Bristol’s $2.5 billion tender for Inhibitex left many industry observers waiting to see what HCV players will do with only two independent pure-play HCV biotechs left. Idenix is eager to get its mid-stage nucleotide free of an FDA partial clinical hold, while Achillion says it has the assets to go it alone in the HCV competition.
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.